Compare Levi Strauss & Co. (LEVI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Novo Nordisk A/S — how do they compare? Levi Strauss & Co. trades at $22.7 (market cap $9.09B), while Novo Nordisk A/S trades at $45.83 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 22.8× Levi Strauss & Co.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| LEVI | NVO | |
|---|---|---|
Market Cap | $9.09B | $207.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $63.98 |
52-Week Low | $17.92 | $35.29 |
Enterprise Value | $10.40B | $222.02B |
Dividend Yield | 2.71% | 3.76% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
